To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate the efficacy, safety and tolerability of vildagliptin compared to voglibose in patients with type 2 diabetes. Please note this study is not being conducted in the United States.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Vildagliptin; Voglibose

Criteria

Inclusion Criteria:

• Diagnosis as Type 2 Diabetes

• Patients who have been placed on dietary therapy/exercise therapy, without achievement of glycemic control

• Outpatients

Exclusion Criteria:

• Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes

• Significant heart diseases

• Significant diabetic complications

Other protocol-defined inclusion/exclusion criteria may apply